Rich Heyman, Metacrine chairman (ARCH)
Metacrine, a Rich Heyman biotech targeting NASH and other liver diseases, raises $85M from IPO
A Rich Heyman-backed startup focusing on NASH treatments, as well as other liver, GI and metabolic diseases, is set to start trading Wednesday and join …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.